Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
Stock Snapshot
With a market cap of 448.15B, Johnson & Johnson(JNJ) trades at $185.75. The stock has a price-to-earnings ratio of 18.03 and currently yields dividends of 2.7%.
On 2025-11-06, Johnson & Johnson(JNJ) stock traded between a low of $185.40 and a high of $187.83. Shares are currently priced at $185.75, which is +0.2% above the low and -1.1% below the high.
Johnson & Johnson(JNJ) shares are trading with a volume of 5.05M, against a daily average of 7.75M.
In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $194.48 and a 52-week low of $140.68.
In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $194.48 and a 52-week low of $140.68.
JNJ News
BTIG lowered the firm’s price target on Zimmer Biomet (ZBH) to $112 from $122 and keeps a Buy rating on the shares following disappointing Q3 results. The firm...
Even though Kenvue's stock was already in a tailspin before the FDA warned pregnant woman that Tylenol posed a health risk, there are still some lingering impac...
Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Inves...
Analyst ratings
56%
of 27 ratingsMore JNJ News
Johnson & Johnson (JNJ) shares have held steady over the past month, showing a slight uptick amid muted headlines for the healthcare giant. Investors may be wat...
Key Points Investors can look at a company's payout ratio to help gauge whether its dividend is sustainable. In some industries, however, companies use adjust...
Johnson & Johnson recently announced plans to launch the first head-to-head study comparing its FcRn blocker IMAAVY™ with other agents in generalized myasthenia...
Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor mod...
Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's ear...
Protagonist Therapeutics (PTGX) drew investor attention after reporting strong Phase 2b results for its drug icotrokinra. This development led Johnson & Johnson...
